Medicine
Augtyro 40 mg capsule
Augtyro 40 mg capsule is a prescription medicine containing Repotrectinib for oral use, marketed by ER Squibb & Sons, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Repotrectinib
- Brand
- Augtyro
- Strength
- 40 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 120 capsules, 60 capsules
- Marketing authorisation holder
- ER Squibb & Sons
- Manufacturer
- ER Squibb & Sons
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EX28 Repotrectinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 December 2023
- Identifiers
- RxCUI 2670649, 2670655, 2696876 +1DailyMed set ID fb526827-40ba-4462-94cf-179ae3b0cb8aNDC 0003-4040Application NDA218213
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 120 capsule in 1 bottle | 0003-4040-12 | ER Squibb & Sons | 5 December 2023 |
| 60 capsule in 1 bottle | 0003-4040-60 | ER Squibb & Sons | 5 December 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Repotrectinib
Clinical summary
Repotrectinib is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC), among other approved uses. It is available as capsules for oral use. MedsAcross supplies Repotrectinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RepotrectinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Augtyro prescribing information (ER Squibb & Sons) · U.S. National Library of Medicine, DailyMed
- Augtyro: European public assessment report (EPAR) · European Medicines Agency
Need Augtyro 40 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.